Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: An observational study in Chinese male

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3129-3135

  Chen, Ming Wei ^a   Ye, Shuai ^a   Zhao, Li Li ^a   Wang, Shen Yi ^a   Li, Yong Xiang ^a   Yu, Chang Jun ^a   Xie, Hui Juan ^a   Wang, You Min ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Adiponectin; Body mass index; Colonoscopy; Colorectal cancer; Insulin resistance; Waist hip ratio

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; TRIACYLGLYCEROL; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; COLORECTAL CANCER; CONTROLLED STUDY; DIET RESTRICTION; EARLY CANCER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR INVASION; WAIST HIP RATIO; ASIAN; BLOOD; BLOOD PRESSURE; BODY MASS; CARCINOMA; COLORECTAL TUMOR; MIDDLE AGED; PATHOLOGY; RISK; RISK FACTOR;

ADIPONECTIN; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BODY MASS INDEX; CARCINOMA; COLORECTAL NEOPLASMS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880278354     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0280-2     Document Type: Article

References (31)

1. Li M, Gu J. Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol. 2005;11(30):4685-8.
2. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-91.
3. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46(12):1594-603.
4. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003;52(2):239-43.
5. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148(3):293-300.
6. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86(3):858-66.
7. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004;27(10):2450-7.
8. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003;52(4):942-7.
9. Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol. 2007;40(2):55-67.
10. Ealey KN, Archer MC. Elevated circulating adiponectin and elevated insulin sensitivity in adiponectin transgenic mice are not associated with reduced susceptibility to colon carcinogenesis. Int J Cancer. 2009;124(9):2226-30.
11. Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol. 2009;34(2):339-44.
12. Kumor A, Daniel P, Pietruczuk M, MaA ecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009;24(3):275-81.
13. Erarslan E, Turkay C, Koktener A, Koca C, Uz B, Bavbek N. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci. 2009;54(4):862-8.
14. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97(22):1688-94.
15. Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, et al. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol. 2010;16(10):1252-7.
16. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96(7):546-53.
17. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, et al. A prospective study of plasma C-peptide, insulin-like growth factor-1, insulin-like growth factor binding protein-1 and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2005;14(4):850-5.
18. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, et al. Increased blood glucose and insulin, body size, and indent colorectal cancer. J Natl Cancer Inst. 1999;91(13):1147-54.
19. Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis. 2011;12(4):234-44.
20. An W, Bai Y, Deng SX, Gao J, Ben QW, Cai QC, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev. 2012;21(2):126-33.
21. Lukanova A, Söderberg S, Kaaks R, Jellum E, Stattin P. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(2):401-2.
22. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G, et al. Components of the metabolic syndrome and colorectal cancer risk: a prospective study. Int J Obes (Lond). 2008;32(2):304-14.
23. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res. 2010;70(13):5430-7.
24. Fukumoto J, Otake T, Tajima O, Tabata S, Abe H, Mizoue T, et al. Adiponectin and colorectal adenoma: Self Defense Forces Health Study. Cancer Sci. 2008;99(4):781-6.
25. Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, et al. Total and high-molecular weight and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Carcinogenesis. 2012;. doi: 10.1093/carcin/bgs133.
26. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101(8):2476-81.
27. Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol. 2009;34(2):339-44.
28. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via adipoR1-and-R2-mediated AMPK activation. Mol Endocrinol. 2010;24(7):1441-52.
29. Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori M, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut. 2008;57(11):1531-8.
30. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I(IGF-1), IGF binding proteins, their biologic interaction, and colorectal cancer. J Natl Cancer Inst. 2002;94(13):972-80.
31. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer. 2007;120(9):2007-12.